Gluten ataxia neurocoeliac disease
Conditions
Interventions
None listed
Sponsors
Vrije Universiteit Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - * 18 years of age - Given informed consent - unexplained ataxia - Group specific: o For gluten sensitivity group: at least positive serology or borderline positive serology o For coeliac disease group: positive serology and positive biopsy results
Exclusion criteria
Exclusion criteria: - No informed consent - Insufficient knowledge of Dutch language and/or inability to understand the information provided. - A known and verified cause of the neurological illness - For MRI specific: Because of the high magnetic field of the MRI scanner, individuals with pacemakers, metallic implants, pregnancy, or certain other conditions (for example a bodyweight over a 140kg) should be excluded unless they are cleared by a clinical radiologist/physiologist.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main study endpoint will be the prevalence of (neuro)coeliac disease related antibody titres in the neurology cohorts, together with the HLA-DQ type and the Marsh classification based on a gastroduodenal biopsy (only if a biopsy has been performed as standard care). | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints will be the effect of a gluten-free diet on antibody titres, neurological symptoms, quality of life and MRI and MR spectroscopy results in patients suspected of gluten ataxia. | — |
Countries
Netherlands
Outcome results
None listed